Get the Stockscreener App
0.0155
9.92%
0.0014
Nls Pharmaceutics Ag stock is traded at $0.0155, with a volume of 24,812.
It is up +9.92% in the last 24 hours and down -8.29% over the past month.
NLS Pharmaceutics AG, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for patients with rare and complex central nervous system disorders. The company is focusing on the development of treatments for narcolepsy, idiopathic hypersomnia, and other rare sleep disorders, as well as neurodevelopmental disorders, such as attention deficit hyperactivity disorder (ADHD). Its lead product candidates include Quilience to treat excessive daytime sleepiness and cataplexy; and Nolazol for the treatment of ADHD. The company also developing NLS-4, a selective dopamine reuptake inhibitor to prevent rare sleep disorders; NLS-3, a repurposed reverse ester of methylphenidate for treatment of ADHD; NLS-8, a melatonin ML1A receptor agonist, improved scopolamine-induced amnesia; NLS-11, a norepinephrine and dopamine reuptake inhibitor and muscarinic M1, M2, M3 receptor antagonist; and NLS-12, a norepinephrine and dopamine reuptake inhibitor and muscarinic M4 receptor antagonist. NLS Pharmaceutics AG was incorporated in 2015 and is based in Zurich, Switzerland.
See More
Previous Close:
$0.0141
Open:
$0.0141
24h Volume:
24,812
Relative Volume:
0.77
Market Cap:
$N/A
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-12.93%
1M Performance:
-8.29%
6M Performance:
+20.15%
1Y Performance:
+17.42%
1-Day Range:
$0.014
$0.0155
1-Week Range:
$0.014
$0.0177
52-Week Range:
$0.0009
$0.0698
Nls Pharmaceutics Ag Stock (NLSPW) Company Profile
Name
Nls Pharmaceutics Ag
Sector
Industry
Phone
41 44 512 21 50
Address
The Circle 6, Zurich
Compare NLSPW with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NLSPW
Nls Pharmaceutics Ag
|
0.0155 | 0 | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
391.02 | 100.52B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
580.70 | 61.43B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
446.51 | 59.29B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
712.20 | 43.09B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
306.05 | 35.42B | 3.81B | -644.79M | -669.77M | -6.24 |
Nls Pharmaceutics Ag Stock (NLSPW) Latest News
Visual analytics tools that track NLS Pharmaceutics AG Equity Warrant performanceTrade Analysis Summary & Safe Capital Growth Tips - Newser
Using Ichimoku Cloud for NLS Pharmaceutics AG technicals2025 Institutional Moves & Community Consensus Picks - Newser
Real time pattern detection on NLS Pharmaceutics AG stock2025 Historical Comparison & Risk Adjusted Buy and Sell Alerts - Newser
Tick level data insight on NLS Pharmaceutics AG volatilityShort Setup & Verified Swing Trading Watchlists - Newser
Predicting NLS Pharmaceutics AG Equity Warrant trend using moving averagesMarket Weekly Review & Growth Focused Investment Plans - Newser
Can NLS Pharmaceutics AG recover in the next quarterJuly 2025 Drop Watch & Accurate Intraday Trading Signals - Newser
Analyzing drawdowns of NLS Pharmaceutics AG Equity Warrant with statistical toolsWeekly Profit Summary & Weekly Top Performers Watchlists - Newser
Key metrics from NLS Pharmaceutics AG Equity Warrant’s quarterly dataNew Guidance & Intraday High Probability Alerts - Newser
Price momentum metrics for NLS Pharmaceutics AG Equity Warrant explainedJuly 2025 Setups & Risk Managed Investment Signals - Newser
Watch for Trend Continuation in NLS Pharmaceutics AG Next Week2025 Market WrapUp & Safe Entry Zone Identification - beatles.ru
NLS Pharmaceutics AG Equity Warrant stock momentum explained2025 Performance Recap & Consistent Income Trade Ideas - Newser
Using R and stats models for NLS Pharmaceutics AG forecastingWall Street Watch & Free Community Supported Trade Ideas - Newser
NLS Pharmaceutics AG Equity Warrant’s volatility index tracking explainedPortfolio Return Summary & Risk Controlled Stock Pick Alerts - Newser
Is NLS Pharmaceutics AG stock entering bullish territoryAnalyst Downgrade & Reliable Price Action Trade Plans - Newser
Top chart patterns to watch in NLS Pharmaceutics AG Equity WarrantTrade Risk Assessment & Low Volatility Stock Suggestions - Newser
Is NLS Pharmaceutics AG Equity Warrant stock entering bullish territory2025 Year in Review & Real-Time Stock Price Movement Reports - Newser
Comparing NLS Pharmaceutics AG Equity Warrant in custom built stock radarsPortfolio Value Report & Real-Time Market Trend Scan - Newser
Building trade automation scripts for NLS Pharmaceutics AG Equity WarrantMarket Growth Summary & Breakout Confirmation Alerts - Newser
Published on: 2025-08-30 21:36:21 - Newser
Custom watchlist performance reports with NLS Pharmaceutics AGJuly 2025 Closing Moves & Free Safe Entry Trade Signal Reports - Newser
Short interest data insights for NLS Pharmaceutics AGEarnings Overview Report & Daily Profit Maximizing Trade Tips - Newser
Risk adjusted return profile for NLS Pharmaceutics AG Equity Warrant analyzedJuly 2025 Selloffs & Safe Entry Point Identification - Newser
Understanding NLS Pharmaceutics AG’s price movementJuly 2025 Levels & Low Drawdown Momentum Ideas - Newser
Developing predictive dashboards with NLS Pharmaceutics AG Equity Warrant dataGap Down & Precise Buy Zone Tips - Newser
Using Bollinger Bands to evaluate NLS Pharmaceutics AG Equity WarrantPortfolio Value Summary & Daily Entry Point Alerts - Newser
NLS Pharmaceutics Extends Merger Deadline with Kadimastem to October 31, 2025. - AInvest
Price action breakdown for NLS Pharmaceutics AG Equity WarrantDividend Hike & Low Risk Growth Stock Ideas - Newser
Using Bollinger Bands to evaluate NLS Pharmaceutics AGQuarterly Investment Review & Low Risk Investment Opportunities - Newser
Analyzing net buyer seller activity in NLS Pharmaceutics AG Equity WarrantMarket Trend Summary & Stepwise Swing Trade Plans - Newser
Detecting support and resistance levels for NLS Pharmaceutics AGInsider Selling & Technical Entry and Exit Tips - Newser
Nls Pharmaceutics Ag Stock (NLSPW) Financials Data
There is no financial data for Nls Pharmaceutics Ag (NLSPW). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
0.96%
1.09%
Cap:
|
Volume (24h):